---
schema_version: "secwatch.filing_event.v1"
accession: "0000947871-26-000034"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2026-01-15T23:59:59+00:00"
generated_at: "2026-05-16T10:18:14.546377+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific to acquire Penumbra for ~$14.5B enterprise value ($374/share)

## Summary
- Deal consideration: ~73% cash, ~27% stock; $374 per Penumbra share; enterprise value ~$14.5B.
- Penumbra Q4 2025 revenue growth 21.4-22.0%; FY2025 revenue ~$1.4B (+17.3-17.5% YoY).
- Transaction expected to close in 2026; subject to Penumbra stockholder approval and customary conditions.
- First full year adj. EPS dilutive $0.06-0.08; neutral to slightly accretive in year two.
- Expands Boston Scientific into mechanical thrombectomy and neurovascular adjacencies.

## SEC filing metadata
- accession: 0000947871-26-000034
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2026-01-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000094787126000034/0000947871-26-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000094787126000034/ss5822817_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000947871-26-000034
- JSON: https://secwatch.observer/filing/0000947871-26-000034.json
- Plain text: https://secwatch.observer/filing/0000947871-26-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.